Biogen/Eisai’s Alzheimer's drug wins marketing nod in Great Britain

seekingalpha08-22

Biogen (NASDAQ:BIIB) and its Japanese partner Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) breakthrough Alzheimer's therapy, Leqembi (lecanemab), has been granted marketing authorization in Great Britain, the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2461399935?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/518929263/image_518929263.jpg","is_english":true,"pubTime":"2024-08-22 17:34","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2461399935","market":"sg","top_or_hot":-1,"title":"Biogen/Eisai’s Alzheimer's drug wins marketing nod in Great Britain","media":"seekingalpha","content":"<div>\n<p>Biogen (NASDAQ:BIIB) and its Japanese partner Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) breakthrough Alzheimer's therapy, Leqembi (lecanemab), has been granted marketing authorization in Great Britain, the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4142646-biogeneisais-alzheimers-drug-wins-marketing-authorization-in-great-britain\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen/Eisai’s Alzheimer's drug wins marketing nod in Great Britain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen/Eisai’s Alzheimer's drug wins marketing nod in Great Britain\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-22 17:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4142646-biogeneisais-alzheimers-drug-wins-marketing-authorization-in-great-britain><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen (NASDAQ:BIIB) and its Japanese partner Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) breakthrough Alzheimer's therapy, Leqembi (lecanemab), has been granted marketing authorization in Great Britain, the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4142646-biogeneisais-alzheimers-drug-wins-marketing-authorization-in-great-britain\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z9Z06.USD","symbol_name":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","start_time":0,"source_url":"https://seekingalpha.com/news/4142646-biogeneisais-alzheimers-drug-wins-marketing-authorization-in-great-britain","article_id":"2461399935","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/518929263/image_518929263.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2461399935","pubTimestamp":1724319294,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Biogen (NASDAQ:BIIB) and its Japanese partner Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) breakthrough Alzheimer's therapy, Leqembi (lecanemab), has been granted marketing authorization in Great Britain, the ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4532":"文艺复兴科技持仓","BK4007":"制药","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","ESAIY":"Eisai Co., Ltd.","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BIIB":"渤健公司","ESALF":"Eisai Co., Ltd.","BK4585":"ETF&股票定投概念","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4588":"碎股","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"Biogen/Eisai的阿尔茨海默氏症药物在英国获得营销认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1,"ESAIY":1,"ESALF":1},"content_text":"Biogen (NASDAQ:BIIB) and its Japanese partner Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) breakthrough Alzheimer's therapy, Leqembi (lecanemab), has been granted marketing authorization in Great Britain, the companies announced on Thursday. Great Britain becomes the first country in Europe to authorize the drug, which targets an underlying cause of Alzheimer's disease. The approval was primarily based on Phase 3 data from Eisai's Clarity AD clinical trial, in which the drug achieved its primary endpoint and all key secondary endpoints with statistically significant results. Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody and said to be the only approved treatment shown to reduce the rate of disease progression and slow cognitive and functional decline in Alzheimer's. In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers. China approved Leqembi in January 2024 as a treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease, becoming the third country to do so after the U.S. and Japan. Eisai (OTCPK:ESALF) (OTCPK:ESAIY) is the lead developer of the drug, with Biogen (BIIB) assisting its commercialization. The companies will co-promote the drug in Great Britain, with Eisai distributing the product as the marketing authorization holder.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2461399935"}